Rising Reimbursement Pressures And Regulatory Hurdles Will Dampen Future Prospects
AN
AnalystLowTarget
Not Invested
Consensus Narrative from 23 Analysts
Published
24 Aug 25
Updated
24 Aug 25
AnalystLowTarget's Fair Value
US$47.73
4.3% undervalued intrinsic discount24 Aug
US$45.66
1Y
-23.7%7D
1.3%1Y
-23.7%7D
1.3%